Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $1.04 billion in net product revenues, representing a 121% year-over-year increase in the first quarter of 2026. The company also recognizes collaboration revenues from its partners like Regeneron REGN, Roche, Novartis and Sanofi, which add to the top line. ALNY’s partnership with Novartis added a fifth approved product, Leqvio. Royalty revenues from its sales have been boosting top-line growth.
To sustain long-term growth, Alnylam has made significant investments to build a broad and promising pipeline capable of driving future revenues. The company is currently advancing several candidates, with key programs including cemdisiran, mivelsiran, zilebesiran and nucresiran.
In 2024, Alnylam granted Regeneron exclusive rights to develop cemdisiran as a monotherapy and in combination with anti-C5 antibodies for complement-mediated indications. Regeneron is evaluating cemdisiran in combination with pozelimab, in a phase III clinical study for paroxysmal nocturnal hemoglobinuria and as a monotherapy and in combination with pozelimab in phase III clinical studies for myasthenia gravis (MG) and geographic atrophy. In 2025, Regeneron reported that cemdisiran monotherapy achieved both the primary and key secondary endpoints in a phase III study for generalized myasthenia gravis and submitted a regulatory filing seeking its U.S. approval in April 2026. Additional global filings are planned for 2026. Subject to approval, Alnylam will earn royalties on the drug’s sales, per their agreement.
Alnylam’s phase II KARDIA program showed that zilebesiran, an RNAi therapy targeting angiotensinogen, was effective both as a standalone treatment and in combination with standard antihypertensive drugs, highlighting its potential as a best-in-class option for patients with high cardiovascular risk. Additional positive results from the KARDIA-3 study, conducted with Roche, demonstrated sustained reductions in systolic blood pressure, improved cardiovascular and renal biomarkers, and a favorable safety profile, with the 300 mg dose showing the strongest benefits.
Based on such results, Alnylam and Roche have initiated dosing in the global phase III ZENITH cardiovascular outcomes study in 2025, which is evaluating the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension.
Alnylam is developing its wholly-owned pipeline candidate, mivelsiran (formerly ALN-APP), for treating early-onset Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). The company expects to initiate a phase II study on mivelsiran for AD soon. Additionally, patient enrollment and dosing are currently ongoing in a separate phase II study of the candidate for CAA.
Nucresiran is Alnylam’s next-generation investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. Last year, the company advanced nucresiran into late-stage development, launching the phase III TRITON-PN study for patients with hereditary ATTR polyneuropathy and the phase III TRITON-CM study for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The continued progress of these and several other clinical-stage pipeline candidates, alongside Alnylam’s marketed therapies, has the potential to meaningfully expand and diversify its commercial portfolio.
ALNY’s Market Competition for Lead Drug Amvuttra
Alnylam’s primary top-line driver is its newest drug, Amvuttra, which is approved for polyneuropathy of hereditary ATTR amyloidosis and ATTR-CM in adults. The drug generated $889.9 million in global sales in first-quarter 2026, representing 187% year-over-year growth, driven by patient demand.
Alnylam’s Amvuttra faces notable competition in the ATTR-CM market from Pfizer’s PFE Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s BBIO Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer’s and BridgeBio’s therapies carry the advantage of oral administration and comparatively lower list prices in the United States.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and Estimates
Shares of Alnylam have plunged 21.4% so far this year against the industry’s 9.3% growth. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price Movement
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 10.09 trailing 12-month sales per share, higher than 2.53 for the industry. However, the stock is trading much below its five-year mean of 18.04.
ALNY Stock Valuation
Estimates for Alnylam’s 2026 earnings have deteriorated from $9.22 to $9.05 per share in the past 60 days, while estimates for 2027 earnings have decreased from $14.31 to $13.24 over the same timeframe.
ALNY Estimate Movement
Alnylam currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).